Monovalent Anti-CD3 Antibodies Effectively Eliminate the TCR-Positive Fraction of TCR-Deleted Allogeneic CAR-T Cells to Prevent GVHD
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Chimeric antigen receptor-transduced T (CAR-T) cell therapy is an effective cell therapy against advanced hematological tumors. However, the use of autologous T cells limits its timely and universal generation. Allogeneic CAR-T cell therapy may be a good alternative as a ready-to-use therapeutic. Graft-versus-host disease (GVHD) is an obstacle for allogeneic CAR-T cells, but can be prevented by TCR deletion through genome editing. However, the remaining TCR-positive cells must be eliminated by costly, large-scale magnetic cell separation. Therefore, an alternative method for removing TCR-positive cells is needed. In this study, we found that monovalent anti-CD3 Abs such as Fab and single-chain variable fragment (scFv), but not whole IgG, induce apoptosis of in vitro expanded T cells, thereby effectively depleting residual TCR-positive T cells during TCR-deleted CAR-T cell generation and ultimately preventing xenogeneic GVHD in vivo. Thus, monovalent anti-CD3 treatment during allogeneic CAR-T cell manufacturing would be an efficient method to prevent GVHD.
Abstract
Chimeric antigen receptor-transduced T (CAR-T) cell therapy is an effective cell therapy against advanced hematological tumors. However, the use of autologous T cells limits its timely and universal generation. Allogeneic CAR-T cell therapy may be a good alternative as a ready-to-use therapeutic. Graft-versus-host disease (GVHD) is an obstacle for allogeneic CAR-T cells, but can be prevented by TCR deletion through genome editing. However, the remaining TCR-positive cells must be eliminated by costly, large-scale magnetic cell separation. Therefore, an alternative method for removing TCR-positive cells is needed. In this study, we found that monovalent anti-CD3 Abs such as Fab and single-chain variable fragment (scFv), but not whole IgG, induce apoptosis of in vitro expanded T cells, thereby effectively depleting residual TCR-positive T cells during TCR-deleted CAR-T cell generation and ultimately preventing xenogeneic GVHD in vivo. Thus, monovalent anti-CD3 treatment during allogeneic CAR-T cell manufacturing would be an efficient method to prevent GVHD.
참고문헌 (29)
- June CH, "CAR T cell immunotherapy for human cancer", Science, 359, pp.1361~1365 (2018)
- Labanieh L, "CAR immune cells : design principles, resistance and the next generation", Nature, 614, pp.635~648 (2023)
- Moradi V, "The paths and challenges of"off-the-shelf"CAR-T cell therapy : an overview of clinical trials", Biomed Pharmacother, 169, pp.115888~ (2023)
- Schuster SJ, "Chimeric antigen receptor T cells in refractory B-cell lymphomas", N Engl J Med, 377, pp.2545~2554 (2017)
- Neelapu SS, "Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma", N Engl J Med, 377, pp.2531~2544 (2017)
- Lv Z, "Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy", Front Immunol, 14, pp.1199145~ (2023)
- Provasi E, "Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer", Nat Med, 18, pp.807~815 (2012)
- Poirot L, "Multiplex genome-edited T-cell manufacturing platform for"off-the-shelf"adoptive T-cell immunotherapies", Cancer Res, 75, pp.3853~3864 (2015)
- Qasim W, "Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells", Sci Transl Med, 9, pp.eaaj2013~ (2017)
- Eyquem J, "Targeting a CAR to the TRAC locus with CRISPR", Cas9 enhances tumour rejection, 2017, pp.543, 113~117
- Georgiadis C, "Long terminal repeat CRISPR-CAR-coupled"universal"T cells mediate potent anti-leukemic effects", Mol Ther, 26, pp.1215~1227 (2018)
- Benjamin R, "Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia : results of two phase 1 studies", Lancet, 396, pp.1885~1894 (2020)
- Ottaviano G, "Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia", Sci Transl Med, 14, pp.eabq3010~ (2022)
- Wesselborg S, "Induction of activation-driven death(apoptosis)in activated but not resting peripheral blood T cells", J Immunol, 150, pp.4338~4345 (1993)
- Carpenter PA, "Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells", J Immunol, 165, pp.6205~6213 (2000)
- Kim H, "CD19", CD22 bispecific chimeric antigen receptor-NK-92 cells are developed and evaluated, 2023, pp.25, 236~
- Osborn MJ, "Evaluation of TCR gene editing achieved by TALENs, CRISPR", Cas9, and megaTAL nucleases, 2016, pp.24, 570~581
- Li HW, "Nonalloreactive T cells prevent donor lymphocyte infusion-induced graft-versus-host disease by controlling microbial stimuli", J Immunol, 189, pp.5572~5581 (2012)
- Brownlie RJ, "T cell receptor signalling networks : branched, diversified and bounded", Nat Rev Immunol, 13, pp.257~269 (2013)
- Juillerat A, "Straightforward generation of ultrapure off-the-shelf allogeneic CAR-T cells", Front Bioeng Biotechnol, 8, pp.678~ (2020)
- Kath J, "CAR NK-92 cell-mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell products", Blood Adv, 7, pp.4124~4134 (2023)
- Lenardo MJ, "Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis", Nature, 353, pp.858~861 (1991)
- Yu XZ, "Induction of apoptosis by anti-CD3 epsilon F(ab’)2 in antigen receptor transgenic murine T cells activated by specific peptide", J Immunol, 157, pp.3420~3429 (1996)
- Valdor R, "Induction and stability of the anergic phenotype in T cells", Semin Immunol, 25, pp.313~320 (2013)
- Youn HD, "Apoptosis of T cells mediated by Ca2+-induced release of the transcription factor MEF2", Science, 286, pp.790~793 (1999)
- Conley JM, "T cells and gene regulation : the switching on and turning up of genes after T cell receptor stimulation in CD8 T cells", Front Immunol, 7, pp.76~ (2016)
- Zhu L, "Role of mitogen-activated protein kinases in activation-induced apoptosis of T cells", Immunology, 97, pp.26~35 (1999)
- Yu XZ, "Enhancement of susceptibility to Fas-mediated apoptosis of TH1 cells by nonmitogenic anti-CD3epsilon F(ab’)2", Transplantation, 69, pp.104~112 (2000)
- Kishimoto H, "Strong TCR ligation without costimulation causes rapid onset of Fas-dependent apoptosis of naive murine CD4+ T cells", J Immunol, 163, pp.1817~1826 (1999)